Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd held its 24th AGM on 27.08.2026, with voting results and scrutinizer's report available on the company's website. The meeting was conducted through video conferencing, with 97610 shareholders on record. Resolutions were passed for the audited financial statements, appointment of a director, and ratification of the cost auditor's remuneration.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd held its 24th Annual General Meeting on August 27, 2026, through video conferencing. The meeting was attended by 71 members, and the proceedings were recorded. The Board of Directors presented the financial statements, and the shareholders ratified the remuneration payable to the Cost Auditors. The meeting also approved granting loans, giving guarantees, and providing securities under section 185 of the Companies Act, 2013.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd (KIMS) has issued a clarification regarding an article published in Dealstreetasia.com stating that the company is in talks to acquire a stake in Renova Hospitals for $52 million. KIMS denies the report as false, baseless, and factually incorrect.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has entered into an Operations and Management Agreement and Call Option Agreement with Aurevia Hospitals Private Limited for an initial term of 5 years.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has allotted 77,02,182 warrants on a preferential basis to Dr. Abhinay Bollineni, Mr. Adwik Bollineni, and Bharas Ventures LLP, raising Rs. 1,499,999,944.50. The warrants are convertible into equity shares within 18 months.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has announced its Q1 FY '27 earnings, with total revenue of INR 1,196 crore, a growth of 36.1% year-on-year and 10.3% on quarter-on-quarter basis. EBITDA of INR 240 crore, a growth of 20.1% on year-on-year and 10.9% on quarter-on-quarter basis. PAT at INR 37 crores in Quarter 1, '27 against INR 85 crore and INR 33 crores in Q1 FY '26 and Q4 FY '26 respectively.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has received in-principle approval from BSE and NSE for the issue and allotment of 77,02,182 warrants convertible into equity shares to promoters/promoter group on a preferential basis.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd (KIMS) has published a newspaper notice for its 24th Annual General Meeting (AGM) to be held on August 27, 2026, through video conferencing. The notice is also available on the company's website.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has dispatched a letter to shareholders regarding the Annual Report for the Financial Year 2025-26 and has also announced the 24th Annual General Meeting (AGM) scheduled to be held on 27th August, 2026.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, along with an Independent Practitioners' Reasonable Assurance Report. The report highlights the company's approach to environmental stewardship, social responsibility, and sound governance.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has submitted its 24th Annual Report for the FY 2025-26, highlighting its expansion with excellence and empathy, with a network of 26 branches across 5 states. The report showcases the company's clinical excellence, patient outreach, and financial performance.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has scheduled its 24th Annual General Meeting to be held on 27th August 2026.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has announced an analyst/institutional investor meeting, Emkay Confluence 2026, scheduled for August 12, 2026, in Mumbai, India. The meeting is subject to change due to exigencies, and no unpublished price-sensitive information will be shared.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has published unaudited financial results for the 1st quarter ended June 30, 2026, in the Financial Express and Navatelangana newspapers, as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has made available the audio recording of its conference call with investors and analysts for Q1 FY27 on its website.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, related to the QIP issue of ₹1,500 crore. The report, issued by CARE Ratings Limited, has been reviewed by the Audit Committee of the Company and is enclosed with the announcement.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has filed a statement of deviation for the quarter ended June 30, 2026, stating that there was no deviation in the utilization of funds raised through a Qualified Institutional Placement.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has announced its unaudited financial results for Q1FY27, showing a 36.1% growth in total revenue and a 20.1% growth in EBITDA. The company's consolidated EPS for the period ended 30th June 2026 is INR 1.04, a degrowth of 47.2% on YoY basis.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has released an investor presentation for unaudited Q1 FY2026 financial results, as per Regulation 30 of SEBI (LODR) Regulations, 2015.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has announced its Q1 2026-27 financial results, with the Board of Directors approving the unaudited standalone and consolidated financial results. The company has also approved a loan of up to ₹650 crores to subsidiaries or associates, and a loan of up to ₹25 crores to a material subsidiary. The financial results are available on the company's website and on the websites of BSE and NSE.